TMDI - Titan Medical Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.8000
+0.0400 (+1.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close2.7600
Open2.8300
Bid2.7300 x 2200
Ask2.7800 x 1800
Day's Range2.6500 - 2.8600
52 Week Range1.0500 - 198.0002
Volume132,751
Avg. Volume253,490
Market Cap87.3M
Beta (3Y Monthly)5.68
PE Ratio (TTM)N/A
EPS (TTM)-2.6020
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire3 days ago

    Titan Medical Annual and Special Meeting Scheduled for Wednesday, May 29, 2019

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces that its 2019 Annual and Special Meeting is scheduled for Wednesday, May 29, 2019 at 12:00 p.m. (Eastern), to be held at the Toronto Hilton Hotel, 145 Richmond Street West, Simcoe Room, Main Lobby. As the Exercise Price Amendment constitutes a “related party transaction” as such term is defined in Multilateral Instrument 61-101.

  • Business Wire11 days ago

    Titan Medical Reports First Quarter 2019 Financial Results

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or “the Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the three months ended March 31, 2019. All financial results are prepared in accordance with International Financial Reporting Standards (“IFRS”) and are reported in U.S. dollars, unless otherwise stated. David McNally, President and CEO of Titan Medical, said, “We continued to make steady progress during the first quarter and recent weeks, moving closer to pivotal milestones in the development of our single-port robotic surgical system.

  • Business Wire24 days ago

    Titan Medical Names Prominent Medical Technology Executive Charles Federico as Chairman of the Board

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces the appointment of Charles W. Federico, age 70, as Chairman of the Company’s Board of Directors, effective immediately. Mr. Federico is assuming the Board seat held by Bruce Wolff, M.D. who has resigned from the Board and is being retained as a Senior Advisor to the Company.

  • Business Wire25 days ago

    Titan Medical Announces Hardware Design Freeze for its Single-port Robotic Surgery System

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces it has achieved hardware design freeze for its single-port robotic surgery system. Hardware design freeze is an essential milestone in the system design process as it allows Titan to complete various design verification and validation activities such as preclinical studies conducted under Good Laboratory Practices (“GLP”) and Summative Human Factors studies, in preparation for submitting an Investigational Device Exemption (“IDE”) to the U.S. Food and Drug Administration (“FDA”) for human confirmatory studies.

  • Business Wirelast month

    Titan Medical to Present at the Bloom Burton & Co. Healthcare Investor Conference

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 30 at 1:30 p.m. Eastern time. The conference will be held April 30-May 1 at the Metro Toronto Convention Centre, in Toronto, Canada. Mr. McNally’s presentation will be webcast live and available for replay in the Investors section of Titan Medical’s website at titanmedicalinc.com/investors.

  • Business Wire2 months ago

    Titan Medical and Teleflex Incorporated Announce Collaboration for Development of Robotic Ligation Technology

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”) and Teleflex Incorporated (TFX), a leading global provider of medical technologies for critical care and surgery, announce a collaboration under which Teleflex’s market-leading polymer ligation technology will be integrated into Titan’s development-stage, single-port robotic surgery system. Teleflex’s Weck® Hem-o-lok® polymer ligation system is a proven ligation technology for vessel sealing with enhanced clip security features that surgeons have used in millions of patients worldwide.

  • Business Wire2 months ago

    Titan Medical to Webcast Business Update Conference Call on March 28, 2019

    Titan Medical Inc. , a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery , announces that management will webcast a conference call on Thursday, March 28 at 4:30 p.m.

  • Business Wire2 months ago

    Titan Medical Closes Public Offering

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce the closing of its previously announced public offering (the “Offering”) pursuant to an agency agreement dated March 18, 2019 between the Company and Bloom Burton Securities Inc. (the “Agent”). The Company closed the Offering on March 21, 2019 and issued 7,352,941 units (the “Units”) for gross proceeds of approximately US $25,000,000. Each Unit was issued at a price of US $3.40 per Unit (the “Offering Price”) and is comprised of one common share of the Company (a “Common Share”) and one warrant entitling the holder to purchase one Common Share at a price of US $4.00 until expiry on March 20, 2024.

  • Business Wire2 months ago

    Titan Medical Announces Filing of Final Prospectus

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce that yesterday it filed and was receipted for a final short form prospectus (the “Final Prospectus”) in connection with the previously announced marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Offering, Titan will issue Units at a price of US $3.40 per Unit for gross proceeds of a minimum of US $20,000,000 and a maximum of US $25,000,000. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”).

  • Business Wire3 months ago

    Titan Medical Announces Pricing of Overnight Marketed Offering

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has priced its previously announced overnight marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Offering, Titan will issue Units at a price of US $3.40 per Unit for total gross proceeds of a minimum of US$20,000,000 and a maximum of US$25,000,000. Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant of the Company (a “Warrant”).

  • Business Wire3 months ago

    Titan Medical Expands Global Intellectual Property Portfolio to 30 Patents Issued and 75 Pending with Receipt of First Patent in China

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that its global intellectual property portfolio has increased to 30 issued patents and 75 pending applications through the recent granting and filing of patent applications directed at aspects of its innovative robotic surgery program. The recently granted Chinese patent describes the smooth and continuously curved articulation of a robotic instrument to position and orient an end-effector in multiple degrees of freedom.

  • Business Wire3 months ago

    Titan Medical to Participate at Upcoming Investment Conferences

    Titan Medical Inc. , a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery , today announced that Company management will be participating in two upcoming investor conferences.

  • Business Wire3 months ago

    Titan Medical Reports 2018 Financial Results

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the year ended December 31, 2018. David McNally, President and CEO, said, “2018 was an exceptionally busy and productive year for Titan Medical as we achieved all milestones related to the development of our SPORT single-port robotic surgery system. “During the fourth quarter we completed the system engineering confidence build for our next-generation SPORT Surgical System, including a new camera system and design enhancements to the surgeon workstation and the patient cart, the two primary components of the system.

  • Business Wire4 months ago

    Peer-Reviewed Paper Featuring Titan Medical’s Single-Port Robotic Surgical Platform in General Surgery Published in Surgical Endoscopy

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that a peer-reviewed multi-faculty paper featuring Titan’s single-port platform has been published in the January 2019 issue of Surgical Endoscopy. The paper highlights the feasibility, safety and ease of use of Titan’s single-port robotic technology for general surgery procedures and is available here.

  • Business Wire5 months ago

    Titan Medical Completes Build of Its Next-Generation Single-Port Robotic Surgical System

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that it has completed the system engineering confidence build for all components of its single-port robotic surgery system. This accomplishment highlights the completion of a new camera system along with the design enhancements of both the surgeon workstation and the patient cart, the two primary components of the system. The engineering confidence build reflects all significant improvements inspired by the Company’s preclinical experience.

  • Business Wire5 months ago

    Titan Medical Affirms Timeline for U.S. and EU Regulatory Submissions by Year-End 2019 for Its Sport Surgical System

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), affirms its regulatory filing timeline with a 510(k) submission expected by the end of 2019 as a result of discussions with the U.S. Food and Drug Administration (“FDA”). The Company plans to complete the required human confirmatory studies under an Investigational Device Exemption (“IDE”) during the second half of 2019 in support of its 510(k) filing. Additionally, the Company confirms that it also expects to file for the CE mark by year-end 2019.

  • Business Wire5 months ago

    Titan Medical Expands Global Patent Portfolio for Single-Port Robotic Surgery with Seven Grants and Notices of Allowance

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces seven new patent grants and notices of allowance related to its single-port robotic surgery technology, including patents covering multi-articulating instruments, robotic system control and user interfaces. Including these new patents and notices, the Company has 28 issued patents and 70 pending patent applications in the U.S., Europe, Canada, Australia, Japan and China. With respect to the technology behind its unique multi-articulating instruments for single-port robotic surgical systems, the Company has been granted Japanese Patent No. 6433595, titled “Actuator and Drive for Manipulating a Tool.” This is the Company’s second patent in Japan.

  • GlobeNewswire6 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals — New Research Emphasizes Economic Growth

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire6 months ago

    Titan Medical to Present at the 30th Annual Piper Jaffray Healthcare Conference

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the 30th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28 at 12:10 p.m. Eastern time. Mr. McNally’s presentation will be webcast live and available for replay in the Investors section of Titan Medical’s website at titanmedicalinc.com/investors. Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery.

  • Business Wire6 months ago

    Abstract Highlighting Titan Medical’s SPORT Surgical System Presented at the American Association of Gynecologic Laparoscopists Global Congress

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces an abstract titled “Reverse Objective Structured Assessment of Technical Skills (Reverse-OSATS) as a means of measuring the capability of the Titan Medical SPORT Surgical System on core surgical principles” was presented yesterday at the American Association of Gynecologic Laparoscopists (AAGL) 2018 Global Congress. The abstract was presented by Chetna Arora, M.D., who also authored the abstract along with Arnold P. Advincula, M.D. (both from Columbia University Medical Center) and William B. Burke, M.D. (Stony Brook Cancer Center).

  • Business Wire6 months ago

    Titan Medical Reports Third Quarter 2018 Financial Results

    Titan Medical Inc. (TMD.TO) (TMDI) (“Titan” or “the Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the three and nine months ended September 30, 2018. All financial results are prepared in accordance with International Financial Reporting Standards (“IFRS”) and are reported in U.S. dollars, unless otherwise stated. David McNally, President and CEO of Titan Medical, said, “During the third quarter and recent weeks we continued to make excellent progress advancing the development of the SPORT Surgical System, including achieving all stated quarterly milestones.

  • Business Wire7 months ago

    Titan Medical to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15 at 2:00 p.m. Eastern time. The Medical Technologies & Diagnostics Forum will be held November 15, 2018 at the Westin Grand Central in New York, NY. Mr. McNally’s presentation will be webcast live and available for replay in the Investors section of Titan Medical’s website at titanmedicalinc.com/investors.

  • Business Wire7 months ago

    Titan Medical to Present at Dawson James Securities 4th Annual Small Cap Growth Conference

    Titan Medical Inc. (“Titan” or the “Company”) (TMD.TO) (TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the Dawson James Securities 4th Annual Small Cap Growth Conference on Tuesday, October 30 at 11:00 a.m. Eastern time. The conference will be held October 29-30, 2018 at Wyndham Grand Hotel in Jupiter, Florida. A copy of Mr. McNally’s presentation will be available on the Corporate Presentation page of Titan Medical’s website at www.titanmedicalinc.com/investors.